Humanin vs MOTS-c: Which Mitochondrial Peptide Fits Your Research Goals?
Quick Answer
Humanin and MOTS-c are both short peptides encoded in mitochondrial DNA, but they serve different research purposes. Humanin is studied mainly for its neuroprotective and cytoprotective properties. MOTS-c is better known for metabolic regulation and its parallels to aerobic exercise at the cellular level. Neither is a substitute for the other, and researchers typically choose based on their specific area of interest.
What Is Humanin?
Humanin is a 21-amino acid peptide first identified in 2001 by researchers studying neurodegeneration . It is encoded in the 16S ribosomal RNA region of the mitochondrial genome, which makes it unusual since most peptides are encoded in the nuclear genome.
How it works:
- Binds to a tripartite receptor complex that includes FPRL1, CNTFR, and IL-27Rα
- Activates cell survival pathways including JAK2/STAT3 and PI3K/Akt
- Suppresses apoptosis (programmed cell death) in neurons and other vulnerable cell types
- Influences insulin sensitivity and lipid metabolism in animal models
Form and availability:
Humanin is synthesized as a short peptide for research use. The analog Humanin-G (HNG), which contains a glycine substitution at position 14, has roughly 1000-fold greater potency than the native form . Most modern research uses HNG rather than native Humanin.
Evidence level:
Most evidence comes from in vitro experiments and rodent models. Human clinical data remains limited. Typical research doses in rodent studies range from 1 to 8 mg/kg .
What Is MOTS-c?
MOTS-c is a 16-amino acid peptide also encoded in mitochondrial DNA, specifically within the 12S rRNA region . It was identified in 2015 by a team led by Changhan David Lee at USC .
How it works:
- Translocates to the cell nucleus in response to metabolic stress
- Activates AMPK (AMP-activated protein kinase), a master regulator of cellular energy balance
- Regulates the folate cycle and de novo purine biosynthesis pathways
- Improves insulin sensitivity and glucose uptake in skeletal muscle cells
Form and availability:
MOTS-c is available as a synthetic peptide for research purposes. It is typically administered subcutaneously or intraperitoneally in animal study designs.
Evidence level:
MOTS-c has a growing body of rodent research and early human observations from aging and exercise studies . Typical research doses in mouse studies range from 5 to 15 mg/kg . Human dosing conventions are not yet standardized.
Comparison Table
| Feature | Humanin | MOTS-c |
|---|---|---|
| Type/Form | 21-amino acid mitochondrial peptide | 16-amino acid mitochondrial peptide |
| Mechanism | Cytoprotective, anti-apoptotic, JAK2/STAT3 and PI3K/Akt activation | AMPK activation, metabolic gene regulation, nuclear translocation |
| Typical research dose | 1 to 8 mg/kg in rodents | 5 to 15 mg/kg in rodents |
| Evidence level | In vitro and rodent dominant, limited human data | Rodent dominant, emerging human observations |
Key Differences
These two peptides share a genome but diverge significantly in what they appear to do.
1. Primary research focus
Humanin research clusters around neurological and cytoprotective applications. Studies have examined its role in models of Alzheimer's disease, stroke, and cardiac ischemia . MOTS-c research tilts heavily toward metabolic health, with several studies exploring parallels to aerobic exercise and caloric restriction .
2. Signaling mechanism
Humanin works largely through cell-surface receptors that trigger survival signaling cascades inside the cell. MOTS-c takes a different route: it moves directly into the nucleus and modulates gene expression from there. These are fundamentally different mechanisms, which is one reason some researchers view them as potentially complementary rather than redundant.
3. Metabolic versus neuroprotective emphasis
Researchers focused on glucose metabolism, insulin sensitivity, and body composition gravitate toward MOTS-c. Those focused on cognitive aging, neuroprotection, or cardiovascular models tend to focus on Humanin. The distinction is not absolute, since both peptides have some overlap in broad aging-related pathways, but the emphasis differs clearly.
4. Logging and tracking complex protocols
When researching multiple mitochondrial peptides at once, keeping clean records matters. Tools like DoseVault are built specifically for logging research peptide cycles, including dose timing, batch notes, and personal observations across compounds.
Can You Stack Them?
Some researchers use Humanin and MOTS-c together, reasoning that their non-overlapping mechanisms could complement each other. One acts at the membrane level on cell survival pathways, the other on metabolic gene regulation from inside the nucleus.
That said, no published human clinical trial has examined this combination directly . Most evidence for either compound alone comes from animal studies, so assumptions about combined effects remain speculative at this stage.
A few practical considerations if you are researching both:
- Log each compound separately with clear dose, timing, and source notes
- Allow enough time between protocol changes to attribute any observations to the right variable
- Review both research dossiers before combining, since the safety profiles are not identical
If you are considering any peptide protocol, consult a licensed clinician first. A knowledgeable provider can help evaluate individual risk, review health history, and identify what to monitor.
Frequently Asked Questions
What is the difference between Humanin and MOTS-c?
Humanin is a 21-amino acid peptide primarily studied for neuroprotection and cytoprotection. MOTS-c is a 16-amino acid peptide focused on metabolic regulation and AMPK activation. Both are encoded in mitochondrial DNA but work through distinct mechanisms.
Can Humanin and MOTS-c be stacked together?
Some researchers explore both together because their mechanisms do not significantly overlap. However, no published human clinical trial has studied this combination directly. Always consult a licensed clinician before combining any peptides.
What dose of Humanin do researchers typically use?
In rodent models, Humanin doses typically range from 1 to 8 mg/kg . The analog Humanin-G (HNG) is often preferred due to significantly higher potency. Human dosing protocols are not standardized and remain under early investigation.
What does MOTS-c do in the body?
MOTS-c activates AMPK, a key energy-sensing enzyme, and regulates pathways tied to glucose uptake, insulin sensitivity, and the folate cycle. It has been described as a potential exercise mimetic in animal research .
Who Picks Each, and When?
Researchers leaning toward Humanin:
- Primary interest in neuroprotection or cognitive aging models
- Studying Alzheimer's-related pathways or amyloid peptide toxicity
- Examining cardiovascular or ischemic protection mechanisms
- Want a cytoprotective mitochondrial peptide with a broad cell survival research history
Researchers leaning toward MOTS-c:
- Primary interest in metabolic health, insulin resistance, or body composition
- Curious about exercise-related cellular signaling without physical exertion as a variable
- Exploring longevity angles tied to AMPK and mitochondrial signaling
- Studying how mitochondrial peptides influence age-related metabolic decline
Related
- Humanin
- MOTS-c
- 5-Amino-1MQ vs MOTS-c
- Epithalon vs MOTS-c
- MOTS-c vs SS-31
- Peptides for Longevity
- How to Reconstitute MOTS-c
Disclaimer: This content is for educational purposes only. It is not medical advice. Humanin and MOTS-c are not FDA-approved for general therapeutic use. Do not begin any peptide protocol without consulting a licensed healthcare provider.
Built by medical professionals, gym rats, and experienced biohackers
Ready to keep your mitochondrial peptide research organized? DoseVault gives you a clean, dedicated space to log doses, cycle timing, batch details, and personal observations for complex peptide protocols. Visit dosevault.app to get started.